Kahraman, SedaErul, EnesSeyyar, MustafaGumusay, OzgeBayram, ErtugrulDemirel, Burcin CakanAcar, Omer2024-10-292024-10-2920231479-66941744-8301https://doi.org/10.2217/fon-2022-1287https://hdl.handle.net/20.500.11776/14594Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.en10.2217/fon-2022-1287info:eu-repo/semantics/closedAccessCDK 46 inhibitorsHER2-negative metastatic breast cancerHR-positiveletrozoleArticleQ2WOS:0009916467000012-s2.0-8515973194737133230Q1